# GLASSIA Infusion Rate Study

> **NCT01651351** · PHASE4 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 30 (actual)

## Conditions studied

- Alpha1-antitrypsin Deficiency
- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Alpha1-proteinase inhibitor
- **BIOLOGICAL:** Placebo: Human albumin 2.5%

## Key facts

- **NCT ID:** NCT01651351
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-31
- **Primary completion:** 2013-01-16
- **Final completion:** 2013-01-16
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01651351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01651351, "GLASSIA Infusion Rate Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01651351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*